Dina Boles
MD, FRCPC
Dr. Dina Boles completed her medical degree at Ain Shams university, Cairo, Egypt in 2008, followed by Anatomical Pathology Residency Program at University of Toronto, ON, Canada from 2012-2018.
She then completed a Surgical Pathology with breast subspecialty Fellowship at Sunnybrook Health Sciences Centre, Toronto, ON, from 2018-2019.
Currently, Dr. Boles is a staff pathologist at Markham Stouffville Hospital, Markham, ON, Canada.
Recent Publications
Saleeb RM, Plant P, Tawedrous E, Krizova A, Brimo F, Evans AJ, Wala SJ, Bartlett J, Ding Q, Boles D, Rotando F, Farag M, Yousef GM. Integrated Phenotypic/Genotypic Analysis of Papillary Renal Cell Carcinoma Subtypes: Identification of Prognostic Markers, Cancer-related Pathways, and Implications for Therapy. Eur Urol Focus. 2018 Sep;4(5):740-748. doi: 10.1016/j.euf.2016.09.002. Epub 2016 Sep 22. PMID: 28753789.
Butz H, Szabó PM, Nofech-Mozes R, Rotondo F, Kovacs K, Mirham L, Girgis H, Boles D, Patocs A, Yousef GM. Integrative bioinformatics analysis reveals new prognostic biomarkers of clear cell renal cell carcinoma. Clin Chem. 2014 Oct;60(10):1314-26. doi: 10.1373/clinchem.2014.225854. Epub 2014 Aug 19. PMID: 25139457.
Lichner Z, Fendler A, Saleh C, Nasser AN, Boles D, Al-Haddad S, Kupchak P, Dharsee M, Nuin PS, Evans KR, Jung K, Stephan C, Fleshner NE, Yousef GM. MicroRNA signature helps distinguish early from late biochemical failure in prostate cancer. Clin Chem. 2013 Nov;59(11):1595-603. doi: 10.1373/clinchem.2013.205450. Epub 2013 Aug 19. PMID: 23958847.
Lichner Z, Fendler A, Saleh C, Nasser AN, Boles D, Al-Haddad S, Kupchak P, Dharsee M, Nuin PS, Evans KR, Jung K, Stephan C, Fleshner NE, Yousef GM. MicroRNA signature helps distinguish early from late biochemical failure in prostate cancer. Clin Chem. 2013 Nov;59(11):1595-603. doi: 10.1373/clinchem.2013.205450. Epub 2013 Aug 19. PMID: 23958847.